Loading...
PHARM logo

Pharming Group N.V.ENXTAM:PHARM Stock Report

Market Cap €1.0b
Share Price
€1.43
€2.11
32.2% undervalued intrinsic discount
1Y102.4%
7D1.6%
Portfolio Value
​
View

Pharming Group N.V.

ENXTAM:PHARM Stock Report

Market Cap: €1.0b

Pharming Group (PHARM) Stock Overview

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. More details

PHARM fundamental analysis
Snowflake Score
Valuation6/6
Future Growth5/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 67.7% below our estimate of its fair value

Earnings are forecast to grow 37.5% per year

Became profitable this year

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 81.1%

Risk Analysis

Volatile share price over the past 3 months compared to the Dutch market

Large one-off items impacting financial results


PHARM Community Fair Values

Create Narrative

See what 53 others think this stock is worth. Follow their fair value or set your own to get alerts.

PHARM logo
Pharming Group

Rare Disease Therapies And Expanded Diagnoses Will Drive Strong Long Term Upside

Catalysts About Pharming Group Pharming Group is a rare disease biotechnology company focused on developing and commercializing innovative therapies for patients with significant unmet medical needs. What are the underlying business or industry changes driving this perspective?
View narrative
€2.11
FV
32.2% undervalued intrinsic discount
3.17%
Revenue growth p.a.
71
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
PHARM logo
Pharming Group

APDS Prevalence Uncertainty And Pipeline Delays Will Test Long-Term Rare Disease Thesis

Catalysts About Pharming Group Pharming Group focuses on rare disease treatments, with commercial therapies for hereditary angioedema and APDS and a late stage program in primary mitochondrial disease. What are the underlying business or industry changes driving this perspective?
View narrative
€1.7
FV
15.7% undervalued intrinsic discount
1.24%
Revenue growth p.a.
25
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
PHARM logo
Pharming Group

Rare Disease Expansion Will Drive Durable Long Term Upside In This Biotech

Catalysts About Pharming Group Pharming Group is a commercial-stage biotech company focused on developing and marketing innovative therapies for rare and ultra-rare diseases. What are the underlying business or industry changes driving this perspective?
View narrative
€2.45
FV
41.5% undervalued intrinsic discount
12.22%
Revenue growth p.a.
118
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
View Stock Community
UNCY logo
Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

View narrative
5.5k
users have viewed this narrative
17users have liked this narrative
0users have commented on this narrative
110users have followed this narrative
US$21.53
69.3% undervalued intrinsic discount
Fair Value
Profit Margin
20%
Future PE
27x
Price in 2030
US$34.67

Pharming Group N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pharming Group
Historical stock prices
Current Share Price€1.43
52 Week High€1.82
52 Week Low€0.66
Beta0.12
1 Month Change7.74%
3 Month Change0.49%
1 Year Change102.40%
3 Year Change29.68%
5 Year Change33.05%
Change since IPO-98.48%

Recent News & Updates

Recent updates

Pharming Group N.V. (AMS:PHARM) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Sep 08
Pharming Group N.V. (AMS:PHARM) Surges 26% Yet Its Low P/S Is No Reason For Excitement

There's No Escaping Pharming Group N.V.'s (AMS:PHARM) Muted Revenues Despite A 29% Share Price Rise

May 10
There's No Escaping Pharming Group N.V.'s (AMS:PHARM) Muted Revenues Despite A 29% Share Price Rise

Pharming Group N.V. (AMS:PHARM) Held Back By Insufficient Growth Even After Shares Climb 26%

Dec 21
Pharming Group N.V. (AMS:PHARM) Held Back By Insufficient Growth Even After Shares Climb 26%

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14
Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23
Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17
Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Shareholder Returns

PHARMNL BiotechsNL Market
7D1.6%5.3%2.6%
1Y102.4%34.2%32.5%

Return vs Industry: PHARM exceeded the Dutch Biotechs industry which returned 34.2% over the past year.

Return vs Market: PHARM exceeded the Dutch Market which returned 32.5% over the past year.

Price Volatility

Is PHARM's price volatile compared to industry and market?
PHARM volatility
PHARM Average Weekly Movement7.8%
Biotechs Industry Average Movement8.5%
Market Average Movement4.9%
10% most volatile stocks in NL Market8.2%
10% least volatile stocks in NL Market2.9%

Stable Share Price: PHARM's share price has been volatile over the past 3 months compared to the Dutch market.

Volatility Over Time: PHARM's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Dutch stocks.

About the Company

FoundedEmployeesCEOWebsite
1988407Fabrice Chouraquiwww.pharming.com

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group N.V. Fundamentals Summary

How do Pharming Group's earnings and revenue compare to its market cap?
PHARM fundamental statistics
Market cap€1.01b
Earnings (TTM)€2.47m
Revenue (TTM)€326.37m
406.5x
P/E Ratio
3.1x
P/S Ratio

Is PHARM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHARM income statement (TTM)
RevenueUS$376.13m
Cost of RevenueUS$45.50m
Gross ProfitUS$330.63m
Other ExpensesUS$327.78m
EarningsUS$2.85m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

May 07, 2026

Earnings per share (EPS)0.0041
Gross Margin87.90%
Net Profit Margin0.76%
Debt/Equity Ratio35.4%

How did PHARM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/06 00:01
End of Day Share Price 2026/04/02 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharming Group N.V. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John SavinEdison Investment Research
Simon ScholesFirst Berlin Equity Research GmbH
Joseph PantginisH.C. Wainwright & Co.